0.7734USD+0.05%Mkt Cap: 170.63M USDP/E: —Last update: 2026-05-26
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap170.63M USD
Enterprise Value100.66M USD
Revenue (TTM)225.00K USD
Gross Profit225.00K USD
Net Income (TTM)-90.60M USD
Revenue/Share0.0010 USD
Last Price0.7734 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees70
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA-1.28
EV/Revenue447.37
P/S761.91
P/B1.39
EPS (TTM)-0.44
EPS (Forward)-0.41
52W Range
0.390020% of range2.350
52W High2.350 USD
52W Low0.3900 USD
Profitability
Gross Margin100.00%
Oper. Margin-8917.78%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.50%
ROA-61.66%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-68.26M USD
CapEx (TTM)618.00K USD
FCF Margin-17939.22%
FCF Yield-23.66%
Net Debt-70.77M USD
Net Debt/EBITDA0.90
Balance Sheet
Debt/Equity0.09
Current Ratio5.75
Quick Ratio5.45
Book Value/Sh0.5690 USD
Cash/Share0.3730 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)4.000 USD
Target Range2.000 USD – 8.000 USD
# Analysts6
Ownership
Shares Out.217.00M
Float166.77M
Insiders0.47%
Institutions48.32%
Short Interest
Short Ratio9.1d
Short % Float16.72%
Short % Out.12.86%
Shares Short27.91M
Short (prev mo.)25.19M
Technical
SMA 500.7687 (+0.6%)
SMA 2001.030 (-24.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)4.38M
Avg Vol (10d)6.55M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—